Daniela Stadler

Daniela Stadler is a scientist at Coriolis Pharma since January 2021, focusing on research regarding particle analysis techniques for Advanced Therapeutic Medicinal Products (ATMPs) and Cell-Based Medicinal Products (CBMPs). Prior to this role, Daniela Stadler served as a postdoctoral researcher in the Institute of Virology at TUM from July 2018 to December 2020 and at HelmholtzZentrum München from May 2017 to June 2018, where research centered on hepatitis B virus and innate defense mechanisms. Educational qualifications include a Dr. rer. nat. in Experimental Medicine from Technische Universität München / HelmholtzZentrum München (2013-2017), an M. Sc. in Molecular Biotechnology from Technical University of Munich (2010-2013), and a B. Sc. in Molecular Biotechnology, also from Technical University of Munich (2007-2010), with a brief educational stint at Karolinska Institutet in 2012.